Nexalin Technology receives USPTO patent for non-invasive DIFS device to treat Alzheimer's and dementia.
Nexalin Technology receives a USPTO patent for its non-invasive Deep Intracranial Frequency Stimulation (DIFS) device used to treat Alzheimer's and dementia. The Gen-2 and Gen-3 brain stimulation devices use a proprietary frequency-based waveform to treat patients without pain or detection. With the global dementia treatment market projected to reach $28 billion by 2030, Nexalin's DIFS technology could revolutionize mental health disorder care.
June 20, 2024
5 Articles